These hypoxia-derived metabolites are potent immunosuppressors that can protect tumor cells from anti-tumor immune responses mediated by tumor-specific CD4+ and CD8+ T cells (Ohta et al, 2006; Sitkovsky et al, 2008). The gene discussed is CD4; the disease is neoplasm.